Congress trades

Exact Sciences Corporation (EXAS)

Medical Diagnostics & Research, listed on NASDAQ.

28 Congress tradeslast filed Apr 3, 2026

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Scan to get
the app

On recordAs of Nov 11, 2026

Kevin Hern reported a $1,001 to $15,000 sale of stock.

In a dependent’s account, traded Mar 24, 2026 and disclosed Apr 3, 2026, 10 days later.

EarningsQ4 FY2025 · reported Feb 13, 2026

Q4 FY2025: Miss on EPS. Revenue beat by 2.0%.

EPS Q4 FY2025

Reported-$0.45
Consensus-$0.11

Revenue Q4 FY2025

Reported$878M
Consensus$861M

Beat 3Miss 3

Every quarter

CongressSTOCK Act disclosures to the House and Senate

20 Congress disclosures shown, from 2 members.

28dMedian delayof the 45 day limit
7 buys · 13 sellsPurchases and sales in the disclosures shown
Every Congress trade in EXASEvery disclosure
Companyfrom the company's filings and listing, as of Nov 10, 2026

About Exact Sciences Corporation

Exchange
NASDAQ
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Chief executive
Kevin T. Conroylast on record
Employees
6,900
Listed since
Feb 1, 2001
Market value
$20.0Blast quoted Mar 23, 2026
Price to earnings (12 mo)
-
Net income per share, as reported (12 mo)
-
Dividend yield
-

www.exactsciences.com

Earnings6 reported quarters

Earnings

QuarterEPSEPS expectedRevenueRevenue expectedResult
Q4 FY2025reported Feb 13, 2026-$0.45-$0.11$878.4M$860.9MEPS missRevenue beat
Q3 FY2025reported Nov 3, 2025$0.24-$0.06$850.7M$810.5MEPS beatRevenue beat
Q2 FY2025reported Aug 6, 2025$0.22-$0.02$811.1M$810.1MEPS beatRevenue in line
Q1 FY2025reported May 1, 2025-$0.54-$0.37$706.8M$688.6MEPS missRevenue beat
Q4 FY2024reported Feb 19, 2025-$0.06-$0.29$713.4M$697.9MEPS beatRevenue beat
Q3 FY2024reported Nov 5, 2024-$0.21-$0.20$708.7M$716.8MEPS missRevenue in line

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.

No earnings call briefs on EXAS yet. Briefs from every company we cover.

Analysts

Analyst ratings and price targets

Past year Each firm's latest target, newest first

Each firm's latest price target on EXAS, newest first
FirmRatingTargetActionDate
MizuhoNeutral$105Target set
Evercore ISIIn Line$105Target set
StifelHold$105Target set
CanaccordHold$105Target set
Piper SandlerNeutral$105Target set
JefferiesHold$105Target set
Craig-HallumHold$105Target set
BarclaysEqual Weight$105Target set
Wells FargoEqual Weight$105Target set
BairdNeutral$105Target set

Each firm's latest target from the past year, with the rating stated with its note. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice.

4 other firms rated EXAS in the past year with no current target listed here. Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 11, 2026.

Proxy statementas filed for fiscal 2024 · proxy filed Apr 29, 2025

Executive pay

Kevin Conroy’s pay as CEO came to $15.5M for fiscal 2024.
ExecutiveSalaryStock awardsOtherTotal
Kevin ConroyChairman, President and Chief Executive Officer$1.1M$13.5M$960K$15.5M
Aaron BloomerExecutive Vice President and Chief Financial Officer$432K$6.0M$752K$7.2M
Jacob OrvilleExecutive Vice President and General Manager, Screening$618K$3.6M$234K$4.4M
Brian BaranickExecutive Vice President and General Manager, Precision Oncology$600K$3.6M$218K$4.4M
Sarah CondellaExecutive Vice President, Human Resources$509K$1.9M$226K$2.6M

The summary compensation table from the proxy statement for fiscal 2024, with titles as filed then. 2 executives who have since left the company are named in that filing and not shown here. Read the filing

STOCK Act20 disclosures of 28 on record · median 28d of the 45 allowed

Congress trades in EXAS

MemberTypeActionAmount disclosedSince the tradeTrade dateDisclosedDelay
Kevin HernDependent childStockSale$1,001 - $15,000n/aPrice history ends Mar 23, 2026Mar 24, 2026Apr 3, 202610d
Josh GottheimerJointStockSale$1,001 - $15,000n/aPrice history ends Mar 23, 2026May 10, 2024Jun 8, 202429d
Josh GottheimerJointStockSale$1,001 - $15,000n/aPrice history ends Mar 23, 2026Feb 1, 2024Mar 7, 202435d
Kevin HernDependent childStockSale$1,001 - $15,000n/aPrice history ends Mar 23, 2026Jan 2, 2024Feb 11, 202440d
Josh GottheimerJointStockSale$1,001 - $15,000n/aPrice history ends Mar 23, 2026Nov 13, 2023Dec 8, 202325d
Josh GottheimerJointStockPurchase$1,001 - $15,000n/aPrice history ends Mar 23, 2026Oct 16, 2023Nov 11, 202326d
Josh GottheimerJointStockSale$1,001 - $15,000n/aPrice history ends Mar 23, 2026Sep 15, 2023Oct 15, 202330d
Josh GottheimerJointStockSale$1,001 - $15,000n/aPrice history ends Mar 23, 2026May 1, 2023Jun 11, 202341d
Josh GottheimerJointStockPurchase$1,001 - $15,000n/aPrice history ends Mar 23, 2026Jan 20, 2023Feb 17, 202328d
Kevin HernJointStockSale$1,001 - $15,000n/aPrice history ends Mar 23, 2026Jan 31, 2023Feb 14, 202314d
Kevin HernJointStockSale$50,001 - $100,000n/aPrice history ends Mar 23, 2026Dec 19, 2022Jan 13, 202325d
Kevin HernDependent childStockSale$1,001 - $15,000n/aPrice history ends Mar 23, 2026May 16, 2022Jun 14, 202229d
Josh GottheimerJointStockSale$1,001 - $15,000n/aPrice history ends Mar 23, 2026Jun 3, 2021Jul 15, 202142d
Kevin HernJointStockPurchase$50,001 - $100,000n/aPrice history ends Mar 23, 2026May 20, 2021Jun 15, 202126d
Kevin HernDependent childStockPurchase$1,001 - $15,000n/aPrice history ends Mar 23, 2026May 20, 2021Jun 15, 202126d
Josh GottheimerJointStockPurchase$1,001 - $15,000n/aPrice history ends Mar 23, 2026Nov 11, 2020Dec 9, 202028d
Josh GottheimerJointStockPurchase$1,001 - $15,000n/aPrice history ends Mar 23, 2026Oct 26, 2020Nov 5, 202010d
Josh GottheimerJointStockSale$1,001 - $15,000n/aPrice history ends Mar 23, 2026Sep 15, 2020Oct 13, 202028d
Kevin HernJointStockPurchase$1,001 - $15,000n/aPrice history ends Mar 23, 2026Jul 27, 2020Aug 15, 202019d
Josh GottheimerJointStockSale$1,001 - $15,000n/aPrice history ends Mar 23, 2026Jun 2, 2020Jul 9, 202037d

We hold no closing prices for any row shown here, so no move is shown. Not investment advice.

Every Congress trade in EXAS filterable by party, chamber, type and account.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.

Data as of Nov 11, 2026.

Methodology · Guide to Form 4 · Guide to the STOCK Act

Questions

What the filings on EXAS show and how current they are.

Which members of Congress have traded EXAS?

Kevin Hern and Josh Gottheimer disclosed EXAS transactions in the filings shown here.

How quickly are EXAS trades disclosed?

Congressional disclosures took a median of 28 days, against the 45 the STOCK Act allows.

Related companies

traded by the same members

See every company we track